Key result
ET-17 highlights renewed clinical interest and active research in endothelin receptor antagonists.
Why the study?
There has been renewed interest in endothelin receptor antagonists for treating various diseases following successful clinical trials such as SONAR in diabetic nephropathy.
Key points are not available for this paper at this time.
Design
Virtual international conference on endothelin research
Follow-up
4 half-days
The ET-17 conference highlighted renewed interest and vibrant research in endothelin receptor antagonists across various diseases, spurred by recent clinical successes like the SONAR trial.
The Seventeenth International Conference on Endothelin (ET-17) was held during 4–7 October 2021 and because of the SARS-CoV-2 pandemic it was held virtually. Sponsored by the American Physiological Society, ET-17 was held over 4 half-days, with exciting studies related to all organ systems presented. Since the Lancet article reporting the successful SONAR clinical trial with endothelin receptor A blockade in diabetic nephropathy, there has been renewed interest in the use of endothelin receptor antagonists in the treatment of a variety of diseases. From the rigorous preclinical studies to the latest clinical trials, ET-17 was full of exciting science, some of which is reported in this special issue. We welcomed new labs to the meeting and everyone left with the impression that ET-related research is a vibrant field with very significant discoveries being made.
No takes yet. Share an insight, caveat, or question.
Gumz et al. (2022) reported an editorial. The Seventeenth International Conference on Endothelin (ET-17) highlighted vibrant research and renewed interest in endothelin receptor antagonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: